Back to results

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Primary Purpose

Rheumatoid Arthritis

Status

Completed

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

Mavrilimumab 30 mg

Mavrilimumab 100 mg

Mavrilimumab 150 mg

Placebo

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring Rheumatoid Arthritis, Mavrilimumab, CAM-3001

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

A diagnosis of adult onset Rheumatoid Arthritis (RA) in line with the protocol
Moderately active disease in line with the protocol
A pre-defined number of swollen joints in line with the protocol
Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)
No evidence of respiratory disease.

Exclusion Criteria:

A rheumatic autoimmune disease other than RA, or significant systemic extra-articular involvement secondary to RA
A history of, or current, inflammatory joint disease other than RA
Previous treatment with the investigational drug
Discontinuation of a biologic DMARD due to lack of efficacy
Non-compliant concurrent medications
Non-compliance with medical history criteria.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Mavrilimumab 30 mg

Mavrilimumab 100 mg

Mavrilimumab 150 mg

Arm Description

Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram [mg] per week) through oral or parenteral route.

Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Outcomes

Primary Outcome Measures

Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85

DAS28 (CRP) calculated swollen joint count (SJC) and tender joint count (TJC) using the 28 joints, general health (GH) using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst), and CRP (milligram per liter [mg/L]). Total score range: 0-9.4, higher score= more disease activity. DAS28 (CRP) less than (<) 3.2 = low disease activity, greater than or equal to (>=) 3.2 to 5.1 = moderate to high disease activity and <2.6= remission. A Day 85 responder was defined as a participant who experienced more than 1.2 decrease from baseline in DAS28 (CRP) score at Day 85.

Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169

ACR20 was defined as >=20 percent (%) improvement, in: SJC and TJC and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and CRP.

Secondary Outcome Measures

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and Day 169 that were absent before treatment or that worsened relative to pretreatment state.

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs)

Any medically significant change in laboratory evaluations were recorded as adverse events. Following parameters were analyzed for laboratory examination: hematology (haemoglobin, absolute neutrophil count, leukocyte count, platelet count), serum chemistry (alanine transaminase, aspartate transaminase, bilirubin, gamma-glutamyl transferase), other serum chemistry (low-density lipoprotein cholesterol, triglycerides), and urinalysis.

Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)

Vital sign assessments included blood pressure, pulse rate, temperature, weight and respiration rate. Vital signs abnormalities reported as TEAEs were reported.

Percentage of Pulmonary Function Test Values Below Threshold Values at Day 169

Pulmonary function testing were performed by spirometry to assess forced expiratory volume in 1 second (FEV1), forced expiratory volume in 6 second (FEV6), and forced vital capacity (FVC). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. The percentage of predicted values of these pulmonary function tests were calculated based on decreases from baseline and categorized as less than or equal to (=<) 15 percent (%), more than (>) 15 to =<20%, and >20%.

Dyspnea Score at Day 169

Borg dyspnea scale is a validated participant reported outcome assessing participant's perceived difficulty in breathing (dyspnea). The scale ranges from 0 (nothing at all) to 10 (maximal difficulty). Higher scores indicate greater difficulty in breathing.

Oxygen Saturation Level at Day 169

Oxygen saturation measured by pulse oximetry which measures the concentration of oxygen in the blood.

Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Responses at Day 169

ACR50 was defined as >=50% improvement, in: SJC and TJC and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

Percentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Responses at Day 169

ACR70 was defined as >=70% improvement, in: SJC and TJC and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

Change From Baseline in Continuous American College of Rheumatology (ACRn) Score at Day 169

ACR score - continuous (ACRn) was defined as the minimum of the percentage improvement in TJC, SJC and the median of the percentage improvements in the other five components of the ACR criteria (participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; disability index of the HAQ; and CRP). Total score range was -100 to 100, where negative numbers indicated worsening and positive numbers indicated improvement.

Percentage of Participants Who Achieved DAS28 (CRP) Response by European League Against Rheumatism (EULAR) Category at Day 169

DAS28 (CRP) response by EULAR category were used to measure individual response as none, moderate, and good, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline >1.2 with baseline DAS28 (CRP) <3.2; moderate response: change from baseline >1.2 with baseline DAS28 (CRP) >=3.2 to less than or equal to (=<) 5.1 or change from baseline >=0.6 to =< 1.2 with baseline DAS28 (CRP) >=3.2 to =<5.1; no response: change from baseline <0.6 or change from baseline >=0.6 and =<1.2 with baseline DAS28 (CRP) >5.1.

Percentage of Participants With DAS28 (CRP) Remission and Low Disease Activity at Day 169

DAS28 (CRP) calculated SJC and TJC using the 28 joints, GH using participant assessment of disease activity (participant rated arthritis activity using the numerical rating scale with 0 = best, 10 = worst), and CRP (mg/L). Total score range: 0-9.4, higher score= more disease activity. Remission was defined as less than 2.6 DAS28 (CRP) score. Low disease activity was defined as less than 3.2 DAS28 (CRP) score.

Mean Change From Baseline in Swollen and Tender Joint Count at Day 169

Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1. Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1.

Mean Change From Baseline in Patient Assessment of Pain at Day 169

Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analogue Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

Mean Change From Baseline in Patient Global Assessment (PGA) of Disease Activity at Day 169

Participants responded to a question, "Considering all the ways your arthritis affects you, how are you feeling today?" by using a 0 - 100 millimeter (mm) VAS, where 0 = very well and 100 = very poorly.

Mean Change From Baseline in Physician Global Assessment of Disease Activity (MDGA) at Day 169

Physician Global Assessment of Arthritis was measured by asking the physician to assess the participant's current arthritis disease activity by placing a vertical line on a 0 to 10 centimeter (cm) VAS, where 0 cm = very good and 10 cm = very bad.

Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Day 169

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range from 0 to 3; where 0 = least difficulty and 3 = extreme difficulty.

Ratio of Change From Baseline in C-Reactive Protein (CRP) at Day 169

CRP is a substance produced by the liver that increases in the presence of inflammation in the body. The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement in underlying disease.

Ratio of Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Day 169

ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. The farther the red blood cells have descended, the greater the inflammatory response.

Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Day 169

The SDAI was the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient global assessment and physician global assessment assessed on 0 - 10 cm VAS; and C-reactive protein (CRP) (milligram per deciliter [mg/dL]). The SDAI total score ranges from 0 to 86, where higher scores indicates greater affection due to disease activity. SDAI remission was defined as a score less than or equal to 3.3.

Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Day 169

The CDAI was the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, patient global assessment and physician global assessment assessed on 0 - 10 cm VAS. The CDAI total score ranges from 0 to 76 where higher scores indicates greater affection due to disease activity. CDAI remission was defined as a score less than or equal to 2.8.

Percentage of Participants With American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission at Day 169

ACR/EULAR remission was defined as swollen joint count (0-66), tender joint count (0-68), CRP (mg/dL) and participant global assessment (0-10) all less than or equal to one.

Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-fatigue) at Day 169

FACIT-F is a 13-item questionnaire questionnaire to measure the degree of fatigue experiences by participants in the previous 7 days. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score) where higher sore represent less fatigue.

Serum Concentrations of Mavrilimumab

Serum concentrations after multiple subcutaneous doses of mavrilimumab were calculated for each cohort (30mg, 100mg and 150mg). Geometric coefficient of variation at Baseline for cohorts 30mg and 150mg were calculated as the negligible mean value was observed.

Percentage of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Mavrilimumab at Any Visit

Immunogenicity assessment included determination of anti-drug (mavrilimumab) antibodies in serum samples. ADA detection measured by using electrochemiluminescence assays.

Full Information

NCT ID

NCT01706926

First Posted

October 3, 2012

Last Updated

August 3, 2016

Sponsor

MedImmune LLC

Collaborators

MedImmune Ltd

1. Study Identification

Unique Protocol Identification Number

NCT01706926

Brief Title

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Official Title

A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Study Type

Interventional

2. Study Status

Record Verification Date

August 2016

Overall Recruitment Status

Completed

Study Start Date

August 2012 (undefined)

Primary Completion Date

December 2013 (Actual)

Study Completion Date

January 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

MedImmune LLC

Collaborators

MedImmune Ltd

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The primary objective of this study is to evaluate the efficacy of 3 subcutaneous doses of mavrilimumab compared with placebo in combination with methotrexate (MTX) in subjects with moderate-to-severe adult onset Rheumatoid Arthritis (RA).

Detailed Description

Despite the therapeutic improvements with recent biologic agents approved for rheumatoid arthritis, there is still significant unmet medical need for the treatment of subjects with this chronic disease to achieve a faster, more complete response, and higher rates of remission. The aim of the study is to explore the optimum dose of mavrilimumab for further clinical development and more fully investigate the efficacy and safety profile of mavrilimumab after longer drug exposure (that is, 24 weeks). The results of this study will form the basis for future clinical studies with mavrilimumab.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, Mavrilimumab, CAM-3001

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

420 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Arm Title

Mavrilimumab 30 mg

Arm Type

Experimental

Arm Description

Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Arm Title

Mavrilimumab 100 mg

Arm Type

Experimental

Arm Description

Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Arm Title

Mavrilimumab 150 mg

Arm Type

Experimental

Arm Description

Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.

Intervention Type

Biological

Intervention Name(s)

Mavrilimumab 30 mg

Other Intervention Name(s)

CAM-3001

Intervention Description

Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks

Intervention Type

Biological

Intervention Name(s)

Mavrilimumab 100 mg

Other Intervention Name(s)

CAM-3001

Intervention Description

Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.

Intervention Type

Biological

Intervention Name(s)

Mavrilimumab 150 mg

Other Intervention Name(s)

CAM-3001

Intervention Description

Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.

Intervention Type

Other

Intervention Name(s)

Placebo

Intervention Description

Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.

Primary Outcome Measure Information:

Title

Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85

Description

Time Frame

Baseline and Day 85

Title

Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169

Description

Time Frame

Day 169

Secondary Outcome Measure Information:

Title

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

Description

Time Frame

Baseline up to Day 169

Title

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs)

Description

Time Frame

Baseline up to Day 169

Title

Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)

Description

Vital sign assessments included blood pressure, pulse rate, temperature, weight and respiration rate. Vital signs abnormalities reported as TEAEs were reported.

Time Frame

Baseline up to Day 169

Title

Percentage of Pulmonary Function Test Values Below Threshold Values at Day 169

Description

Time Frame

Day 169

Title

Dyspnea Score at Day 169

Description

Time Frame

Day 169

Title

Oxygen Saturation Level at Day 169

Description

Oxygen saturation measured by pulse oximetry which measures the concentration of oxygen in the blood.

Time Frame

Day 169

Title

Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Responses at Day 169

Description

Time Frame

Day 169

Title

Percentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Responses at Day 169

Description

Time Frame

Day 169

Title

Change From Baseline in Continuous American College of Rheumatology (ACRn) Score at Day 169

Description

Time Frame

Baseline up to Day 169

Title

Percentage of Participants Who Achieved DAS28 (CRP) Response by European League Against Rheumatism (EULAR) Category at Day 169

Description

Time Frame

Day 169

Title

Percentage of Participants With DAS28 (CRP) Remission and Low Disease Activity at Day 169

Description

Time Frame

Day 169

Title

Mean Change From Baseline in Swollen and Tender Joint Count at Day 169

Description

Time Frame

Baseline and Day 169

Title

Mean Change From Baseline in Patient Assessment of Pain at Day 169

Description

Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analogue Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

Time Frame

Baseline and Day 169

Title

Mean Change From Baseline in Patient Global Assessment (PGA) of Disease Activity at Day 169

Description

Time Frame

Baseline and Day 169

Title

Mean Change From Baseline in Physician Global Assessment of Disease Activity (MDGA) at Day 169

Description

Time Frame

Baseline and Day 169

Title

Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Day 169

Description

Time Frame

Baseline and Day 169

Title

Ratio of Change From Baseline in C-Reactive Protein (CRP) at Day 169

Description

Time Frame

Baseline, Day 169

Title

Ratio of Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Day 169

Description

Time Frame

Baseline, Day 169

Title

Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Day 169

Description

Time Frame

Day 169

Title

Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Day 169

Description

Time Frame

Day 169

Title

Percentage of Participants With American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission at Day 169

Description

ACR/EULAR remission was defined as swollen joint count (0-66), tender joint count (0-68), CRP (mg/dL) and participant global assessment (0-10) all less than or equal to one.

Time Frame

Day 169

Title

Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-fatigue) at Day 169

Description

Time Frame

Baseline and Day 169

Title

Serum Concentrations of Mavrilimumab

Description

Time Frame

Baseline, Day 8, 15, 29, 85, 141, and 169

Title

Percentage of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Mavrilimumab at Any Visit

Description

Immunogenicity assessment included determination of anti-drug (mavrilimumab) antibodies in serum samples. ADA detection measured by using electrochemiluminescence assays.

Time Frame

Day 1 to Day 169

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

80 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: A diagnosis of adult onset Rheumatoid Arthritis (RA) in line with the protocol Moderately active disease in line with the protocol A pre-defined number of swollen joints in line with the protocol Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) No evidence of respiratory disease. Exclusion Criteria: A rheumatic autoimmune disease other than RA, or significant systemic extra-articular involvement secondary to RA A history of, or current, inflammatory joint disease other than RA Previous treatment with the investigational drug Discontinuation of a biologic DMARD due to lack of efficacy Non-compliant concurrent medications Non-compliance with medical history criteria.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Marius Albulescu, MD

Organizational Affiliation

MedImmune Ltd

Official's Role

Study Director

Facility Information:

Facility Name

Research Site

City

Ciudad Autonoma de Buenos Aire

Country

Argentina

Facility Name

Research Site

City

Rosario

Country

Argentina

Facility Name

Research Site

City

San Miguel de Tucuman

Country

Argentina

Facility Name

Research Site

City

Plovdiv

Country

Bulgaria

Facility Name

Research Site

City

Sofia

Country

Bulgaria

Facility Name

Research Site

City

Santiago

Country

Chile

Facility Name

Research Site

City

Vina del Mar

Country

Chile

Facility Name

Research Site

City

Barranquilla

Country

Colombia

Facility Name

Research Site

City

Bogota

Country

Colombia

Facility Name

Research Site

City

Bruntal

Country

Czech Republic

Facility Name

Research Site

City

Jihlava

Country

Czech Republic

Facility Name

Research Site

City

Ostrava - Trebovice

Country

Czech Republic

Facility Name

Research Site

City

Praha 2

Country

Czech Republic

Facility Name

Research Site

City

Praha 4

Country

Czech Republic

Facility Name

Research Site

City

Zlin

Country

Czech Republic

Facility Name

Research Site

City

Tallinn

Country

Estonia

Facility Name

Research Site

City

Hildesheim

Country

Germany

Facility Name

Research Site

City

Köln

Country

Germany

Facility Name

Research Site

City

Magdeburg

Country

Germany

Facility Name

Research Site

City

Budapest

Country

Hungary

Facility Name

Research Site

City

Debrecen

Country

Hungary

Facility Name

Research Site

City

Gdynia

Country

Poland

Facility Name

Research Site

City

Grodzisk Mazowiecki

Country

Poland

Facility Name

Research Site

City

Katowice

Country

Poland

Facility Name

Research Site

City

Krakow

Country

Poland

Facility Name

Research Site

City

Warszawa

Country

Poland

Facility Name

Research Site

City

Wroclaw

Country

Poland

Facility Name

Research Site

City

Barnaul

Country

Russian Federation

Facility Name

Research Site

City

Kazan

Country

Russian Federation

Facility Name

Research Site

City

Moscow

Country

Russian Federation

Facility Name

Research Site

City

Novosibirsk

Country

Russian Federation

Facility Name

Research Site

City

St. Petersburg

Country

Russian Federation

Facility Name

Research Site

City

Yaroslavl

Country

Russian Federation

Facility Name

Research Site

City

Belgrade

Country

Serbia

Facility Name

Research Site

City

Niska Banja

Country

Serbia

Facility Name

Research Site

City

Durban

Country

South Africa

Facility Name

Research Site

City

Barcelona

Country

Spain

Facility Name

Research Site

City

Santiago de Compostela

Country

Spain

Facility Name

Research Site

City

Donetsk

Country

Ukraine

Facility Name

Research Site

City

Kharkiv

Country

Ukraine

Facility Name

Research Site

City

Kiev

Country

Ukraine

Facility Name

Research Site

City

Lutsk

Country

Ukraine

Facility Name

Research Site

City

Vinnytsia

Country

Ukraine

12. IPD Sharing Statement

Learn more about this trial

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

We'll reach out to this number within 24 hrs

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Rheumatoid Arthritis

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial